D. A. Singh

1.1k total citations
12 papers, 847 citations indexed

About

D. A. Singh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, D. A. Singh has authored 12 papers receiving a total of 847 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in D. A. Singh's work include Colorectal Cancer Treatments and Studies (7 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers) and Lung Cancer Treatments and Mutations (4 papers). D. A. Singh is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers) and Lung Cancer Treatments and Mutations (4 papers). D. A. Singh collaborates with scholars based in United States. D. A. Singh's co-authors include Hedy L. Kindler, Everett E. Vokes, Sreenivasa Nattam, Gershon Y. Locker, Theodore Karrison, Walter M. Stadler, Gregory Friberg, Mark Kozloff, David Taber and Abraham H. Dachman and has published in prestigious journals such as Journal of Clinical Oncology, European Journal of Cancer and Cancer Chemotherapy and Pharmacology.

In The Last Decade

D. A. Singh

12 papers receiving 832 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
D. A. Singh United States	9	576	266	215	210	189	12	847
Xiang Hu China	21	474 0.8×	302 1.1×	230 1.1×	173 0.8×	200 1.1×	62	979
Katrina S. Pedersen United States	15	661 1.1×	220 0.8×	202 0.9×	293 1.4×	170 0.9×	73	970
Haitian Quan China	17	662 1.1×	383 1.4×	492 2.3×	115 0.5×	137 0.7×	30	1.3k
Kazuhiko Yonekura Japan	15	764 1.3×	624 2.3×	474 2.2×	296 1.4×	139 0.7×	23	1.3k
J.L. Breau France	9	778 1.4×	468 1.8×	385 1.8×	111 0.5×	207 1.1×	21	1.2k
Satoshi Yuki Japan	19	819 1.4×	435 1.6×	201 0.9×	244 1.2×	189 1.0×	129	1.1k
Valerie Poulart United States	13	684 1.2×	283 1.1×	116 0.5×	114 0.5×	249 1.3×	17	1.0k
Hiroyuki Okabe Japan	16	584 1.0×	297 1.1×	243 1.1×	126 0.6×	89 0.5×	37	850
Jian-Ming Xu China	12	578 1.0×	341 1.3×	167 0.8×	98 0.5×	116 0.6×	15	818
Elena Maccaroni Italy	17	545 0.9×	299 1.1×	247 1.1×	101 0.5×	287 1.5×	54	944

Countries citing papers authored by D. A. Singh

Since Specialization

Citations

This map shows the geographic impact of D. A. Singh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. A. Singh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. A. Singh more than expected).

Fields of papers citing papers by D. A. Singh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. A. Singh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. A. Singh. The network helps show where D. A. Singh may publish in the future.

Co-authorship network of co-authors of D. A. Singh

This figure shows the co-authorship network connecting the top 25 collaborators of D. A. Singh. A scholar is included among the top collaborators of D. A. Singh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. A. Singh. D. A. Singh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

1.

Nimeiri, Halla, D. A. Singh, Kristen Kasza, et al.. (2009). The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium. Investigational New Drugs. 28(6). 854–858. 5 indexed citations

2.

Ramanathan, Ramesh K., Chandra P. Belani, D. A. Singh, et al.. (2009). A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemotherapy and Pharmacology. 64(4). 777–783. 225 indexed citations

3.

Undevia, Samir D., Federico Innocenti, Jacqueline Ramı́rez, et al.. (2008). A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. European Journal of Cancer. 44(12). 1684–1692. 54 indexed citations

4.

Singh, D. A., David Taber, Rafat Ansari, et al.. (2006). A phase II trial of the epothilone B analog BMS-247550 in patients (pts) with hepatobiliary cancer (HBC): An updated analysis. Journal of Clinical Oncology. 24(18_suppl). 14050–14050. 10 indexed citations

5.

Ajani, Jaffer A., D. A. Singh, Daniel G. Haller, et al.. (2006). Multicenter Phase II Trial of S-1 Plus Cisplatin in Patients With Untreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology. 24(4). 663–667. 81 indexed citations

6.

El-Khoueiry, Anthony B., Syma Iqbal, D. A. Singh, et al.. (2006). A randomized phase II non-comparative study of Ispinesib given weekly or every three weeks in metastatic colorectal cancer. A California Cancer Consortium Study (CCC-P). Journal of Clinical Oncology. 24(18_suppl). 3595–3595. 9 indexed citations

7.

Ramanathan, Ramesh K., Chandra P. Belani, D. A. Singh, et al.. (2006). Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial. Journal of Clinical Oncology. 24(18_suppl). 4010–4010. 47 indexed citations

8.

Kindler, Hedy L., Gregory Friberg, D. A. Singh, et al.. (2005). Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology. 23(31). 8033–8040. 360 indexed citations

9.

Ajani, Jaffer A., Alexandria T. Phan, J. C. Yao, et al.. (2005). Multi-center phase II study of S-1 plus cisplatin in patients with advanced gastric carcinoma (AGC). Journal of Clinical Oncology. 23(16_suppl). 4024–4024. 7 indexed citations

10.

Kindler, Hedy L., Gregory Friberg, Walter M. Stadler, et al.. (2004). Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial. Journal of Clinical Oncology. 22(14_suppl). 4009–4009. 33 indexed citations

11.

Undevia, Samir D., Federico Innocenti, Jacqueline Ramı́rez, et al.. (2004). A dose-escalation study of the quinoxaline antitumor agent R(+)XK469 (XK) in patients with refractory solid tumors. Journal of Clinical Oncology. 22(14_suppl). 2021–2021. 2 indexed citations

12.

Kindler, Hedy L., Gregory Friberg, Walter M. Stadler, et al.. (2004). Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial. Journal of Clinical Oncology. 22(14_suppl). 4009–4009. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact